期刊文献+

2型糖尿病脂蛋白代谢及颗粒异常与心血管风险的研究进展 被引量:2

原文传递
导出
摘要 2007年至2008年我国糖尿病的流行病学调查显示中国糖尿病与糖尿病前期患病率分别高达9.7%和15.5%。糖尿病患者其脑血管疾病和卒中增加2-4倍,同时有80%的糖尿病患者死于心血管事件,每年有44%的成人终末期肾病由糖尿病肾病引起口0。有关流行病学调查结果显示,普通人群血脂异常的发生率为20%-40%,而糖尿病患者合并血脂异常者约占60%。并且我国流行病学研究资料还表明:血脂异常是冠心病发病的危险因素,其作用强度与西方人群相同;我国人群血清总胆固醇水平增高不仅增加冠心病发病危险,
出处 《中华糖尿病杂志》 CAS 2012年第4期242-244,共3页 CHINESE JOURNAL OF DIABETES MELLITUS
  • 相关文献

参考文献1

  • 1The China National Diabetes and Metabolie Disorders Study Group. Prevalcnce of Diabetes among Men and Women in China[J].New England Journal of Medicine,2010.1090-1101.

同被引文献30

  • 1赵文华,张坚,由悦,满青青,李红,王春荣,翟屹,李莹,金水高,杨晓光.中国18岁及以上人群血脂异常流行特点研究[J].中华预防医学杂志,2005,39(5):306-310. 被引量:523
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5228
  • 3Chan DC, Watts GF. Dyslipidaemiain the metabolic syndrome and type 2 diabetes: pathogenesis, priorities,pharmacotherapies[J]. Expert Opin Pharmacother, 2011, 12 (1):13-30.
  • 4Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)[J].JAMA,2001, 285(19):2486-2497.
  • 5Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy report of the thirty- person/ten- country panel[J]. J Intern Med, 2006, 259(3):247-258.
  • 6Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on best practices[J]. Clin Chem, 2009, 55(3):407-419.
  • 7Sniderman AD, Williams K, Contois JH, et al. A meta- analysis of lowdensity lipoprotein cholesterol, non- high- density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk[J].Circ Cardiovasc Qual Outcomes,2011, 4(3):337-345.
  • 8Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation[J]. Diabetes Care, 2008, 31(4): 811-822.
  • 9Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists[J]. J Clin Lipidol, 2011,5(5): 338-367.
  • 10Ganda OP, Jumes CG, Abrahamson M J, et al. Quantification of concordance and discordance between apolipoprotein- B and the currently recommended non-HDL-cholesterol goals for cardiovascular risk assessment in patients with diabetes and hypertriglyceridemia[J].Diabetes Res Clin Pract,2012,97 (1):51-56.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部